Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL

Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) R/r DLBCL, an aggressive cancer with limited options, is the second indica... Biopharmaceuticals, Oncology, FDA Novartis, tisagenlecleucel, B-cell lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news